Press Coverage and Latest Announcements
PRESS RELEASES
February 23, 2023
Delfi Promotes Jenn Buechel to President and Chief Operating Officer
February 16, 2023
Delfi Hires Lee-Ann Smith-Freeman as Vice President of Legal
November 18, 2022
Positive Liver Cancer Detection Data Published in Cancer Discovery Shows Further Promise of Delfi’s AI Liquid Biopsy Platform
October 26, 2022
Researchers to Present Proof-of-Concept Liver Cancer Detection Data Using the DELFI Platform at AASLD The Liver Meeting® 2022
September 12, 2022
Delfi Diagnostics Selected as the Liquid Biopsy Partner for 4-IN-THE-LUNG-RUN: A Large-Scale European Lung Cancer Screening Study
August 23, 2022
Delfi Diagnostics Adds Finance and Market Access Leadership as it Prepares for Commercial Launch
July 18, 2022
Delfi Diagnostics Announces $225M Series B Financing
July 12, 2022
Jessica Meng Joins Delfi Diagnostics as Chief Commercial Officer
June 22, 2022
Delfi Diagnostics Appoints Jacob Van Naarden to its Board of Directors
May 17, 2022
Delfi Diagnostics Enters into Broad Research Agreement with Top U.S. Cancer Center
May 9, 2022
Delfi Diagnostics Initiates 15,000-Patient Prospective Lung Cancer Screening Trial
April 4, 2022
Delfi Researchers and Founders to Present at American Association for Cancer Research (AACR) 2022 Annual Meeting
March 30, 2022
Delfi Diagnostics Appoints Liz Homans to its Board of Directors
March 24, 2022
Delfi Diagnostics Adds Reimbursement, Regulatory Leaders to Management Team
October 21, 2021
Delfi Bolsters Leadership Team with Three Key Hires
October 7, 2021
Doug Schenkel Joins Delfi Diagnostics as Chief Financial Officer
August 20, 2021
Delfi Liquid Biopsy Shows Promise for Reducing Lung Cancer Deaths
June 23, 2021
Dr. Peter Bach Joins Delfi Diagnostics as Chief Medical Officer
March 31, 2021
Delfi Diagnostics Begins Enrollment for Prospective Lung Cancer
Screening Trial Ahead of Planned Commercial Test
February 17, 2021
Industry Leaders Tara Maddala and Allison Ryan Join Delfi Diagnostics Leadership Team
January 16, 2021
Delfi Diagnostics Announces $100 Million Series A Financing to Develop a New Class of Early Detection Liquid Biopsy for Multiple Cancers
NEWS ARTICLES
The Baltimore Sun
January 29, 2023
Baltimore researchers say AI could help reduce disparities, improve access in health care
Baltimore Business Journal
October 7, 2022
Leaders in Health Care 2022: Dr. Victor Velculescu, Delfi Diagnostics
Business Insider
September 6, 2022
21 Most Promising Health Tech Startups According to VCs 2022
San Francisco Business Times
August 30, 2022
Early-cancer detection company takes on billion-dollar competitors
Wall Street Journal
July 18, 2022
Delfi Diagnostics Gathers $225M for Cancer Blood Tests
GenomeWeb
May 17, 2022
Delfi Diagnostics, Memorial Sloan Kettering Partner to Advance Cancer Screening Technology
Precision Oncology News
May 9, 2022
Delfi Diagnostics Begins Second, Larger Prospective Lung Cancer Screening Trial
Fierce Biotech
March 7, 2022
Fierce Medtech’s 2021 Fierce 15
Fierce Biotech
August 20, 2021
Delfi Diagnostics’ AI-based blood test detects 80% of early-stage lung cancer cases, study finds
Stat News
June 23, 2021
Peter Bach, Industry Critic, Joins Company Aiming to Make Blood Tests to Detect Cancer
GenomeWeb
March 31, 2021
Delfi Diagnostics Starts Prospective Lung Cancer Screening Trial
FierceBiotech
January 13, 2021
Delfi Diagnostics Raises $100M for a New Approach
to Screening Blood for Cancer
GenomeWeb
February 5, 2020
Methylation, Fragmentation Analyses Remain at Forefront
of Early Detection Liquid Biopsy Development